Evidence map›Paper›PMID 25610755›Full record

ArticleTissue barriers2014

Pathogen-inspired drug delivery to the central nervous system.

Rebecca L McCall, Joseph Cacaccio, Eileen Wrabel, Mary E Schwartz, Timothy P Coleman, Rachael W Sirianni

Abstract read
In one paragraph

Article in Tissue barriers, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Nanoparticle-Based Therapeutics for Brain Injury.Advanced healthcare materials · 2018
    Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Rebecca L McCallBarrow Brain Tumor Research Center; Barrow Neurological Institute ; Phoenix, AZ USA.
Joseph CacaccioBlue Ocean Biomanufacturing , Worcester, MA USA.
Eileen WrabelNemucore Medical Innovations, Inc. ; Worcester, MA USA.
Mary E SchwartzNemucore Medical Innovations, Inc. ; Worcester, MA USA.
Timothy P ColemanBlue Ocean Biomanufacturing , Worcester, MA USA ; Nemucore Medical Innovations, Inc. ; Worcester, MA USA ; Center for Translational Cancer Nanomedicine; Northeastern University ; Boston, MA USA ; Foundation for the Advancement of Personalized Medicine Manufacturing ; Phoenix, AZ USA.
Rachael W SirianniBarrow Brain Tumor Research Center; Barrow Neurological Institute ; Phoenix, AZ USA.

Funding

Physico-Chemical Nanocharacterization CoreU54CA151881 · NCI · NORTHEASTERN UNIVERSITY · PI TORCHILIN, VLADIMIR P · 2010 to 2014
$12.4M
NCI NIH HHS U54 CA151881
6 · The paper itself

Abstract

For as long as the human blood-brain barrier (BBB) has been evolving to exclude bloodborne agents from the central nervous system (CNS), pathogens have adopted a multitude of strategies to bypass it. Some pathogens, notably viruses and certain bacteria, enter the CNS in whole form, achieving direct physical passage through endothelial or neuronal cells to infect the brain. Other pathogens, including bacteria and multicellular eukaryotic organisms, secrete toxins that preferentially interact with specific cell types to exert a broad range of biological effects on peripheral and central neurons. In this review, we will discuss the directed mechanisms that viruses, bacteria, and the toxins secreted by higher order organisms use to enter the CNS. Our goal is to identify ligand-mediated strategies that could be used to improve the brain-specific delivery of engineered nanocarriers, including polymers, lipids, biologically sourced materials, and imaging agents.

Indexed as

braincentral nervous systemDGL, dendrigraft poly-l-lysineDrug deliveryGABA, gamma-aminobutyric acid receptorMMP-2, matrix metalloprotease-2nAchR, nicotinic acetylcholine receptorNCAM, neural cell adhesion moleculeNMDA, N-methyl-D-aspartatepathogenPEG, polyethylene glycolPEI, polyethyleniminepeptidetoxin

Identifiers

PMID25610755
PMCPMC4292043

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.